When was Translate Bio founded?

Translate Bio was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is Translate Bio located?

Translate Bio is headquartered in Lexington, United States. It is registered at Lexington, Massachusetts.

How many employees does Translate Bio have?

As of Mar 01, 2026, the latest employee count at Translate Bio is 50 - 199.

Is Translate Bio a funded company?

Translate Bio is a funded company, having raised a total of $138M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 30, 2011.

When was the latest funding round of Translate Bio?

Translate Bio's latest funding was a $***** Post IPO round on Jun 23, 2020, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $882M in funding in 2026 to date.

Where does Translate Bio rank among its competitors?

Translate Bio ranks 763rd amongst 3274 active competitors, of which 1102 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Translate Bio?

Translate Bio's top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Translate Bio - 2026 Company Profile, Funding & Competitors

Company Details

Developer of RNA therapeutics to activate therapeutic protein expression. The lead candidate MRT5005 for the treatment of cystic fibrosis. It delivers RNA encoding fully functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to the lung epithelial cells through nebulization. It has also developed mRNA vaccines for infectious disease pathogens including SARS-CoV-2, influenza, and others.

Website: www.translate.bio
Social
Phone Number: +1 **********
Registered Address: Lexington, Massachusetts

Key Metrics

Founded Year

2011

Location

Lexington, United States

Stage

Acquired

Total Funding

$138M in 6 rounds

Latest Funding Round

Post IPO, Jun 23, 2020, $*****

Investors

Atlas Venture & 16 more

Ranked

763^rd among 3274 active competitors

Employee Count

50 - 199 as on Mar 01, 2026

Similar Companies

Alnylam & 1161 more

Exit Details

Acquired by Sanofi (Aug 03, 2021)

View Translate Bio's full profile

Translate Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
RANA THERAPEUTICS, INC. CIN: 451858251 , United States, Active	Dec 31, 1999	-	146 (As on Dec 31, 2021)	-

Translate Bio got acquired by Sanofi on Aug 03, 2021.

Click here to take a look at Translate Bio's acquisition in detail

Translate Bio has raised a total funding of $138M over 6 rounds. Its first funding round was on Nov 30, 2011. Its latest funding round was a Post IPO round on Jun 23, 2020 for $*****. 1 investor participated in its latest round. Translate Bio has 17 institutional investors.

Here is the list of recent funding rounds of Translate Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 23, 2020	4845866	Post IPO	5610528	1040686	6590076	3783386
May 07, 2019	2188297	Post IPO	9550112	3811268	3064740	7220985
Jan 04, 2017	8908372	Series B	3270487	2628903	8177585	Atlas Venture & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Translate Bio's funding rounds and investors

Translate Bio's employee count trend

Translate Bio has 50 - 199 employees as of Mar 26. Here is Translate Bio's employee count trend over the years:

Uncover Translate Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Translate Bio include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Translate Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	Temasek, The Grosvenor Funds & 7 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
763rd	Translate Bio 2011, Lexington (United States), Acquired	Developer of RNA therapeutics to activate therapeutic protein expression	$138M	Brookside Capital, Atlas Venture & 15 others	46/100